Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.